Navigation Links
Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers
Date:3/11/2008

Three Hospitals in Western Pennsylvania Earn Designation

PITTSBURGH, March 11 /PRNewswire/ -- Highmark Blue Cross Blue Shield has named Allegheny General Hospital, UPMC Presbyterian Shadyside and UPMC Passavant as Blue Distinction Centers for Complex and Rare Cancers.

Complex and rare cancers comprise approximately 15 percent of new cancer cases each year, making it difficult for patients to locate or research facilities with oncologists or surgical teams that are experienced in treating these specific malignancies.

Blue Distinction Centers for Complex and Rare Cancers are facilities within participating Blue Cross and Blue Shield network service areas that offer comprehensive inpatient cancer care programs for adults, delivered by multidisciplinary teams with subspecialty training and distinguished clinical expertise in treating the following complex and rare subtypes of cancer:

-- acute leukemia (inpatient/non-surgical)

-- bladder cancer

-- bone cancer

-- brain cancer -- primary

-- esophageal cancer

-- gastric cancer

-- head and neck cancers

-- liver cancer

-- ocular melanoma

-- pancreatic cancer

-- rectal cancer

-- soft tissue sarcomas

-- thyroid cancer -- medullary or anaplastic

The Blue Distinction Centers for Complex and Rare Cancers designation is focused primarily on multidisciplinary treatment planning and complex, major surgical treatments.

"This program supports Highmark's consumerism approach to give members a greater hand in their health by providing tools to help members make informed choices about their health care," said Carey Vinson, M.D., vice president for quality and performance management at Highmark Blue Cross Blue Shield. "The Blue Distinction Centers designation offers members reliable quality-based information pertaining to Blue network-participating facilities when selecting a provider."

Among other selection criteria, these hospitals met the following thresholds necessary to be named as a Blue Distinction Centers for Complex and Rare Cancers:

-- has multidisciplinary team input, including sub-specialty trained

teams for complex and rare cancers and demonstrated depth of expertise

across cancer disciplines in medicine, surgery, radiation oncology,

pathology and radiology

-- demonstrates ongoing quality management and improvement programs for

cancer care

-- demonstrates an ongoing commitment to using clinical data registries

and providing access to appropriate clinical research for complex and

rare cancers

-- demonstrates sufficient volume of experience in treating rare and

complex cancers

Blue Distinction Centers for Complex and Rare Cancers were developed in strategic collaboration with the National Comprehensive Cancer Network (NCCN) and input from a panel of leading clinicians and professional organizations.

Blue Distinction(R) is a designation awarded by Blue Cross and Blue Shield companies to medical facilities that have demonstrated expertise in delivering quality health care. The designation is based on rigorous, evidence-based selection criteria established in collaboration with leading clinicians, medical societies and professional organizations.

With the current areas, including cardiac care and bariatric surgery already in place, Highmark Blue Cross Blue Shield will have a more comprehensive program focused on quality specialty care compared to other health plans. This designation is for 18 months, and institutions that are a part of the program also are subject to periodic re-evaluation as criteria continue to evolve.

Note: Designation as Blue Distinction Centers means these facilities' overall experience and aggregate data met objective criteria established in collaboration with expert clinicians' and leading medical societies' recommendations. Individual outcomes may vary. To find out which services are covered under your policy at any facilities, please call your local Blue Cross and/or Blue Shield Plan.

About Highmark Blue Cross Blue Shield

As one of the state's leading health insurers with nearly 70 years of community involvement, Pittsburgh-based Highmark Blue Cross Blue Shield serves 3.1 million members. The company's mission is to provide access to affordable, quality health care enabling individuals to live longer, healthier lives. Highmark Blue Cross Blue Shield employs more than 5,000 people in the region and provides the resources to give its members a greater hand in their health.

Highmark Blue Cross Blue Shield is an independent licensee of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans.


'/>"/>
SOURCE Highmark
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ROBODOC(R) Announces Patent Cross Licensing Agreement With IBM
2. BioCrossroads Launches www.biocrossroadslinx.com and Releases Report on Biopharma Discovery and Development Contract Services
3. Holy Cross Hospital Selects Allscripts Electronic Health Record
4. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
5. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
6. Blue Cross and Blue Shield of Texas Launches an Integrated Medical-Dental Health Program
7. Emmy(R)- and Golden Globe(R)-Nominated Actress Marcia Cross to Join Lifetime Networks and Members of Congress From Both Parties at Capitol Hill Press Conference
8. Farmers Across the U.S. Realize Double-Digit Yield Advantage From DEKALB(R) Corn Seeds With Triple-Stacked Traits
9. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
10. Biomaxx Systems Inc. Selected as Technical Consultant By Southern Cross Agricultural Developments
11. CrossFire Beilstein Database Exceeds Ten Million Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology:
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):